Atezolizumab (Tecentriq) for Stage IV Cancer
Also known as: Tecentriq, MPDL3280A
A PD-L1 inhibitor (vs. PD-1) that blocks immune evasion from the tumor side, with approvals across lung, liver, and breast cancers.
Mechanism of Action
Unlike PD-1 inhibitors, atezolizumab targets PD-L1 on tumor cells and tumor-infiltrating immune cells, preventing engagement with PD-1 on T cells. This approach preserves PD-L2 signaling, potentially maintaining immune homeostasis. The engineered Fc region minimizes antibody-dependent cellular cytotoxicity of PD-L1+ T cells.
General mechanism: Anti-PD-L1 monoclonal antibody with engineered Fc. Blocks tumor-expressed PD-L1 while preserving PD-L2 signaling.
Current Evidence
IMpower trials established atezolizumab in first-line NSCLC (with bevacizumab + chemotherapy), SCLC, and hepatocellular carcinoma. IMpassion130 reported outcomes in clinical trials in PD-L1+ triple-negative breast cancer.
Clinical Status: FDA-approved for NSCLC, SCLC, hepatocellular carcinoma, urothelial carcinoma, and melanoma.
Safety Profile
Similar to PD-1 inhibitors but potentially lower pneumonitis risk. Immune-related adverse events manageable with standard protocols.
Key Research Questions
- Does PD-L1 targeting offer advantages over PD-1 targeting in specific tumor types?
- What is the role of PD-L2 preservation in treatment outcomes?
- Can atezolizumab combinations with metabolic interventions improve response?